Dasotraline Pediatric ADHD Study

Status:
Completed

Trial end date:
2016-07-01

Target enrollment:

Participant gender:

This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.

Phase 2/Phase 3

Sunovion